AnaptysBio - Overview
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Rosnilimab
ANB032
Imsidolimab
ANB033
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Contact
Toggle
Overview
Rosnilimab
ANB032
Imsidolimab
ANB033
Partnerships
Pipeline
DEVELOPMENT STAGE & ANTICIPATED MILESTONES
THERAPEUTIC
INDICATION
ANTIBODY
PROGRAM
LEAD OPTIMIZATION
IND-ENABLING
PHASE 1
PHASE 2
PHASE 3
ANB032: Anti-BTLA Agonist
Inflammatory Diseases
IND Q4 2022;
Initiate Phase 2
Trial H1 2023
Rosnilimab (ANB030):
Anti-PD-1 Agonist
Alopecia Areata
AZURE: Top-Line Data
Q1 2023
Imsidolimab (ANB019):
Anti-IL-36R
Generalized Pustular
Psoriasis
ANB033: Anti-CD122 Antagonist
Inflammatory Diseases
Phase 1 Top-Line
Data Anounced
April 2022
IND Submission
H1 2024
Top-Line Data
Q4 2023